Determining if EBV Infection Contributes to Breast Carcinogenesis: Does LMP-1-Mediated Upregulation of EGFR and Bcl-x Affect Breast Cancer Pathogenesis
Abstract
Most human breast cancer cells are derived from epithelial cells. Previously studies indicated that about 20% of breast cancer patients carrying tumor cells with overexpression of Her-2/Neu. Herceptin, an antagonist antibody against Her-2/Neu, has been used in clinic for the treatment of breast cancers overexpressing Her-2/Neu. We found that EGFR and Her-2/Neu are highly overexpressed in tumor cells in approximately 30% and 23% of human breast cancer tumor samples, respectively. Interestingly, Overexpression of EGFR and Overexpression of Her-2/Neu do not overlap in most of breast cancer tumor samples. These results suggested that patients with breast cancers should receive different treatments based on their gene expression profiles. For example, breast cancer patients carrying tumors with overexpression of Her-2/Neu should be treated with Her-2/Neu antagonists such as Herceptin, while patients carrying tumors with overexpression of EGFR should be treated with EGFR antagonists.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2002
- Accession Number
- ADA408770
Entities
People
- Genhong Cheng
Organizations
- University of California, Los Angeles